FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282961610> ?p ?o ?g. }

• W4282961610 endingPage "103747" @default.
• W4282961610 startingPage "103747" @default.
• W4282961610 abstract "Non-cytotoxic therapy has changed the treatment paradigm for advanced non-small cell lung cancer (NSCLC) patients. With unique mechanisms of action, these agents have decidedly improved survival and have demonstrated an improved toxicity profile. However, the real-life experience of the patient, which is commonly assessed by health-related quality of life (HRQoL) measurement, is not clearly established with this new generation of lung cancer treatments. The heterogeneity created by specific patient subgroups and different therapeutics calls for a tailored-approach to analyzing patient-reported outcomes. The objective of this systematic review was to assess the methodological quality of HRQoL analysis in Randomized Clinical Trials (RCTs) involving biologic agents to treat NSCLC.A systematic literature search was performed using Medline, Embase, and Web of Science databases to identify NSCLC RCTs published between January 1st, 2000 and January 1st, 2020 reporting HRQoL measures. Only RCTs that both enrolled previously untreated patients with advanced NSCLC and had HRQoL analysis were included.4203 abstracts were screened, of which only 85 RCTs met inclusion and exclusion criteria for analysis. The most applied HRQoL assessment tools were the EORTC-QLQ-C30 (47, 55.3 %), and EORTC-QLQ-LC13 (35, 41.2 %). The median number of verified CONSORT-PRO Extension criteria in the included trials was 3, and only in 10 (11.8 %) trials were all criteria well-documented. Notably, only 21 (24.7 %) RCTs performed subgroup analyses to specifically evaluate HRQoL in different patient populations.QoL reporting in clinical trials is inconsistent and the quality of QoL measures adopted in a majority of trials is suboptimal. Considering the fact that NSCLC is a biologically diverse disease and that the treatments differ based on patient and tumor-specifics, efforts should be pursued to tailor QoL measures for different subsets of this patient population in addition to mandating QoL reporting in clinical trials. We believe that this is necessary to understand the real-life experience of lung cancer patients in the era of personalized medicine." @default.
• W4282961610 created "2022-06-17" @default.
• W4282961610 creator A5020651485 @default.
• W4282961610 creator A5037575235 @default.
• W4282961610 creator A5039491281 @default.
• W4282961610 creator A5042284345 @default.
• W4282961610 creator A5048183782 @default.
• W4282961610 creator A5064718704 @default.
• W4282961610 creator A5081067899 @default.
• W4282961610 creator A5082750269 @default.
• W4282961610 creator A5088670404 @default.
• W4282961610 creator A5089793106 @default.
• W4282961610 date "2022-08-01" @default.
• W4282961610 modified "2023-09-30" @default.
• W4282961610 title "Assessing the methodological quality of quality-of-life analyses in first-line non-small cell lung cancer trials: A systematic review" @default.
• W4282961610 cites W1537213946 @default.
• W4282961610 cites W1842042263 @default.
• W4282961610 cites W2005501262 @default.
• W4282961610 cites W2070309415 @default.
• W4282961610 cites W2098931866 @default.
• W4282961610 cites W2101566396 @default.
• W4282961610 cites W2104156681 @default.
• W4282961610 cites W2105258029 @default.
• W4282961610 cites W2126660668 @default.
• W4282961610 cites W2142960568 @default.
• W4282961610 cites W2150049760 @default.
• W4282961610 cites W2151204647 @default.
• W4282961610 cites W2238083898 @default.
• W4282961610 cites W2273595029 @default.
• W4282961610 cites W2527905628 @default.
• W4282961610 cites W2897807341 @default.
• W4282961610 cites W2922636999 @default.
• W4282961610 cites W2945590213 @default.
• W4282961610 cites W2963868343 @default.
• W4282961610 cites W2984767473 @default.
• W4282961610 cites W2994642443 @default.
• W4282961610 cites W2996433778 @default.
• W4282961610 cites W3012698727 @default.
• W4282961610 cites W3134759823 @default.
• W4282961610 doi "https://doi.org/10.1016/j.critrevonc.2022.103747" @default.
• W4282961610 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35717006" @default.
• W4282961610 hasPublicationYear "2022" @default.
• W4282961610 type Work @default.
• W4282961610 citedByCount "3" @default.
• W4282961610 countsByYear W42829616102022 @default.
• W4282961610 countsByYear W42829616102023 @default.
• W4282961610 crossrefType "journal-article" @default.
• W4282961610 hasAuthorship W4282961610A5020651485 @default.
• W4282961610 hasAuthorship W4282961610A5037575235 @default.
• W4282961610 hasAuthorship W4282961610A5039491281 @default.
• W4282961610 hasAuthorship W4282961610A5042284345 @default.
• W4282961610 hasAuthorship W4282961610A5048183782 @default.
• W4282961610 hasAuthorship W4282961610A5064718704 @default.
• W4282961610 hasAuthorship W4282961610A5081067899 @default.
• W4282961610 hasAuthorship W4282961610A5082750269 @default.
• W4282961610 hasAuthorship W4282961610A5088670404 @default.
• W4282961610 hasAuthorship W4282961610A5089793106 @default.
• W4282961610 hasConcept C126322002 @default.
• W4282961610 hasConcept C142724271 @default.
• W4282961610 hasConcept C143998085 @default.
• W4282961610 hasConcept C159110408 @default.
• W4282961610 hasConcept C168563851 @default.
• W4282961610 hasConcept C17744445 @default.
• W4282961610 hasConcept C177713679 @default.
• W4282961610 hasConcept C1862650 @default.
• W4282961610 hasConcept C189708586 @default.
• W4282961610 hasConcept C199539241 @default.
• W4282961610 hasConcept C204787440 @default.
• W4282961610 hasConcept C2776256026 @default.
• W4282961610 hasConcept C2777596629 @default.
• W4282961610 hasConcept C2779473830 @default.
• W4282961610 hasConcept C2779951463 @default.
• W4282961610 hasConcept C535046627 @default.
• W4282961610 hasConcept C71924100 @default.
• W4282961610 hasConceptScore W4282961610C126322002 @default.
• W4282961610 hasConceptScore W4282961610C142724271 @default.
• W4282961610 hasConceptScore W4282961610C143998085 @default.
• W4282961610 hasConceptScore W4282961610C159110408 @default.
• W4282961610 hasConceptScore W4282961610C168563851 @default.
• W4282961610 hasConceptScore W4282961610C17744445 @default.
• W4282961610 hasConceptScore W4282961610C177713679 @default.
• W4282961610 hasConceptScore W4282961610C1862650 @default.
• W4282961610 hasConceptScore W4282961610C189708586 @default.
• W4282961610 hasConceptScore W4282961610C199539241 @default.
• W4282961610 hasConceptScore W4282961610C204787440 @default.
• W4282961610 hasConceptScore W4282961610C2776256026 @default.
• W4282961610 hasConceptScore W4282961610C2777596629 @default.
• W4282961610 hasConceptScore W4282961610C2779473830 @default.
• W4282961610 hasConceptScore W4282961610C2779951463 @default.
• W4282961610 hasConceptScore W4282961610C535046627 @default.
• W4282961610 hasConceptScore W4282961610C71924100 @default.
• W4282961610 hasLocation W42829616101 @default.
• W4282961610 hasLocation W42829616102 @default.
• W4282961610 hasOpenAccess W4282961610 @default.
• W4282961610 hasPrimaryLocation W42829616101 @default.
• W4282961610 hasRelatedWork W2066421181 @default.
• W4282961610 hasRelatedWork W2089933404 @default.
• W4282961610 hasRelatedWork W2113390573 @default.

• next